Bristol Myers Squibb Gets Positive Opinion for Esophageal-Cancer Treatment From European Medicines Agency
June 25 2021 - 7:31AM
Dow Jones News
By Dave Sebastian
Bristol Myers Squibb said it has received positive opinion for
Opdivo, its treatment of esophageal or gastroesophageal junction
cancer, from the Committee for Medicinal Products for Human Use of
the European Medicines Agency.
The company on Friday said the European Commission, which has
the authority to approve medicines, will now review the
recommendation.
The committee's positive opinion is based on a phase three trial
of Opdivo, Bristol Myers Squibb said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
June 25, 2021 07:30 ET (11:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
